1.The Rare and Challenging Presentation of Gastric Cancer during Pregnancy: A Report of Three Cases.
Sergio PACHECO ; Enrique NORERO ; Claudio CANALES ; José Miguel MARTÍNEZ ; María Elisa HERRERA ; Carolina MUÑOZ ; Nicolás JARUFE
Journal of Gastric Cancer 2016;16(4):271-276
Pregnancy-associated gastric cancer is extremely rare. In many cases, it is diagnosed at an advanced stage because the symptoms during pregnancy are generally overlooked. We report three cases of gastric cancer during pregnancy with various outcomes. The first case included a patient with stage IV gastric cancer who received palliative chemotherapy. This patient had a preterm birth and died 7 months after diagnosis. The second case received neoadjuvant chemotherapy during pregnancy and a total gastrectomy was performed after delivery. She then received adjuvant chemoradiotherapy. This patient developed pulmonary metastasis and died of recurrence 41 months after surgery. In the third case, a distal subtotal gastrectomy was performed at week 14 of pregnancy, with no complications. The patient received adjuvant chemoradiotherapy. She is currently without recurrence 14 months after surgery. In patients with pregnancy-associated gastric cancer, treatment decisions are predominantly influenced by clinical stage and gestational age at diagnosis.
Carcinoma, Signet Ring Cell
;
Chemoradiotherapy, Adjuvant
;
Diagnosis
;
Drug Therapy
;
Gastrectomy
;
Gestational Age
;
Humans
;
Neoplasm Metastasis
;
Pregnancy*
;
Premature Birth
;
Recurrence
;
Stomach Neoplasms*
2.Internal and external validation of indocyanine green plasma disappearance rate to discard liver grafts before procurement
Sergio CORTESE ; Katherine PLUA ; Alejandro J. PEREZ-ALONSO ; María Savoie HONTORIA ; David PACHECO ; Natalia Zambudio CARROLL ; Manuel Ángel Barrera GÓMEZ ; José María Pérez PEÑA ; Álvaro G. Morales TABOADA ; María Fernández MARTÍNEZ ; Sergio Hernández KAKAURIDZE ; Ana María MATILLA ; José Ángel López BAENA ; José Manuel ASENCIO
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(4):458-465
Background:
s/Aims: Thirty percent of liver grafts in donors after brain death (DBD) in Spain are rejected by procurement surgeons owing to marginal graft quality. Poor donor indocyanine green (ICG) clearance has been associated with graft discard and malfunction. This study aimed to internally and externally validate the predictive value of ICG-plasma disappearance rate (ICG-PDR) to reject grafts before donation and set a cut-off to avoid missing any potential effective donors.
Methods:
Between March 2017 and August 2023, ICG clearance test was performed immediately before procurement in 71 DBD. The surgeon was blinded to test results. Univariate and multivariate analyses were performed to detect independent predictors of graft discard. Discrimination and calibration of predictors were assessed and a cut-off with 100% specificity was set. External validation was performed on 17 donors evaluated by three other transplantation teams.
Results:
In the training cohort, 30 of 71 grafts were discarded for transplantation. ICG-PDR was the only donor variable independently associated with graft discard. The area under receiver operating characteristic curve for ICG-PDR was 0.875 (95% confidence interval: 0.768–0.947) and good calibration was observed. Below a PDR of 13.5%/min, no graft was accepted for transplantation. These results were successfully validated using the external cohort of donors.
Conclusions
ICG clearance test performed in DBD was internally and externally validated to predict liver graft discard. It could be used as a screening tool before donation to avoid unnecessary costs of travel and human resources.
3.Internal and external validation of indocyanine green plasma disappearance rate to discard liver grafts before procurement
Sergio CORTESE ; Katherine PLUA ; Alejandro J. PEREZ-ALONSO ; María Savoie HONTORIA ; David PACHECO ; Natalia Zambudio CARROLL ; Manuel Ángel Barrera GÓMEZ ; José María Pérez PEÑA ; Álvaro G. Morales TABOADA ; María Fernández MARTÍNEZ ; Sergio Hernández KAKAURIDZE ; Ana María MATILLA ; José Ángel López BAENA ; José Manuel ASENCIO
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(4):458-465
Background:
s/Aims: Thirty percent of liver grafts in donors after brain death (DBD) in Spain are rejected by procurement surgeons owing to marginal graft quality. Poor donor indocyanine green (ICG) clearance has been associated with graft discard and malfunction. This study aimed to internally and externally validate the predictive value of ICG-plasma disappearance rate (ICG-PDR) to reject grafts before donation and set a cut-off to avoid missing any potential effective donors.
Methods:
Between March 2017 and August 2023, ICG clearance test was performed immediately before procurement in 71 DBD. The surgeon was blinded to test results. Univariate and multivariate analyses were performed to detect independent predictors of graft discard. Discrimination and calibration of predictors were assessed and a cut-off with 100% specificity was set. External validation was performed on 17 donors evaluated by three other transplantation teams.
Results:
In the training cohort, 30 of 71 grafts were discarded for transplantation. ICG-PDR was the only donor variable independently associated with graft discard. The area under receiver operating characteristic curve for ICG-PDR was 0.875 (95% confidence interval: 0.768–0.947) and good calibration was observed. Below a PDR of 13.5%/min, no graft was accepted for transplantation. These results were successfully validated using the external cohort of donors.
Conclusions
ICG clearance test performed in DBD was internally and externally validated to predict liver graft discard. It could be used as a screening tool before donation to avoid unnecessary costs of travel and human resources.
4.Internal and external validation of indocyanine green plasma disappearance rate to discard liver grafts before procurement
Sergio CORTESE ; Katherine PLUA ; Alejandro J. PEREZ-ALONSO ; María Savoie HONTORIA ; David PACHECO ; Natalia Zambudio CARROLL ; Manuel Ángel Barrera GÓMEZ ; José María Pérez PEÑA ; Álvaro G. Morales TABOADA ; María Fernández MARTÍNEZ ; Sergio Hernández KAKAURIDZE ; Ana María MATILLA ; José Ángel López BAENA ; José Manuel ASENCIO
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(4):458-465
Background:
s/Aims: Thirty percent of liver grafts in donors after brain death (DBD) in Spain are rejected by procurement surgeons owing to marginal graft quality. Poor donor indocyanine green (ICG) clearance has been associated with graft discard and malfunction. This study aimed to internally and externally validate the predictive value of ICG-plasma disappearance rate (ICG-PDR) to reject grafts before donation and set a cut-off to avoid missing any potential effective donors.
Methods:
Between March 2017 and August 2023, ICG clearance test was performed immediately before procurement in 71 DBD. The surgeon was blinded to test results. Univariate and multivariate analyses were performed to detect independent predictors of graft discard. Discrimination and calibration of predictors were assessed and a cut-off with 100% specificity was set. External validation was performed on 17 donors evaluated by three other transplantation teams.
Results:
In the training cohort, 30 of 71 grafts were discarded for transplantation. ICG-PDR was the only donor variable independently associated with graft discard. The area under receiver operating characteristic curve for ICG-PDR was 0.875 (95% confidence interval: 0.768–0.947) and good calibration was observed. Below a PDR of 13.5%/min, no graft was accepted for transplantation. These results were successfully validated using the external cohort of donors.
Conclusions
ICG clearance test performed in DBD was internally and externally validated to predict liver graft discard. It could be used as a screening tool before donation to avoid unnecessary costs of travel and human resources.